📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
100 announcements match the current filters (relevance ≥ 5).
JKIPL Standalone Revenue Grows 27% to ₹180.32 Cr; Strategic Inventory Build-up to ₹70 Cr
Jinkushal Industries reported a 27% YoY growth in standalone turnover to ₹180.32 crore for the nine months ended December 2025, driven by robust export demand. The company has strategically increased its overseas inventory from historical levels of ₹15 crore to ₹70 crore to enable faster delivery and capture higher margins from refurbished equipment. While consolidated profits are temporarily impacted by inter-company eliminations and a sales deferral in Mexico due to tariff clarifications, the company has successfully diversified into South Africa and the UAE. Management expects consolidated performance to improve significantly as this high-value inventory is monetized in coming quarters.
Key Highlights
Standalone turnover increased 27% YoY to ₹180.32 crore from ₹141.48 crore.
Strategic overseas inventory build-up reached a record ₹70 crore to support retail and direct sales.
Mexico market experienced temporary demand deferral due to new import tariff clarifications in December 2025.
Geographic diversification expanded focus to South Africa and UAE to mitigate regional market risks.
IPO proceeds are being actively deployed for brand building and international expansion of the HexL brand.
👀 What to Watch
Investors should monitor the pace of inventory liquidation at the overseas subsidiary, as converting the ₹70 crore stock into sales is critical for consolidated profitability. Watch for further updates on Mexico's import tariff situation which could impact near-term export volumes.
Jinkushal Industries Approves Q3 FY26 Results; Reports Zero Deviation in IPO Fund Utilization
Jinkushal Industries Limited approved its unaudited financial results for the quarter ended December 31, 2025, with an unmodified auditor's report. The company confirmed it has utilized ₹93.55 crore of the ₹94.10 crore allocated from its IPO proceeds for working capital and corporate purposes. There were no deviations or variations in fund usage compared to the prospectus. This transparency regarding the ₹116.15 crore total IPO raise provides clarity on the company's capital management.
Key Highlights
Approved Q3 FY26 unaudited financial results with an unmodified limited review report.
Total IPO proceeds raised: ₹11,615.45 Lakhs (Fresh Issue: ₹10,454.40 Lakhs).
Utilized ₹7,213.10 Lakhs for long-term working capital out of ₹7,267.50 Lakhs allocated.
Fully utilized ₹2,142.00 Lakhs allocated for General Corporate Purposes.
Only ₹54.40 Lakhs remains unutilized from the allocated objects as of Dec 31, 2025.
👀 What to Watch
Investors should review the detailed financial statements for revenue and profit growth trends following the IPO. The clean report on fund utilization suggests disciplined management of capital.
Jinkushal Industries Approves Q3 FY26 Results; Reports No Deviation in IPO Fund Utilization
Jinkushal Industries Limited (JKIPL) has approved its unaudited financial results for the quarter ended December 31, 2025, with a clean audit report. The company also submitted a statement of fund utilization for its recent IPO, showing that Rs. 9355.10 Lakhs has been deployed out of the allocated Rs. 9409.50 Lakhs. Specifically, Rs. 7213.10 Lakhs was directed toward long-term working capital, while Rs. 2142.00 Lakhs was used for general corporate purposes. There were no deviations or variations from the objects stated in the prospectus, indicating disciplined capital management.
Key Highlights
Board approved unaudited standalone and consolidated financial results for the quarter ended December 31, 2025.
Auditors issued an unmodified Limited Review Report, confirming no material misstatements in financial reporting.
Total IPO proceeds raised amounted to Rs. 11,615.45 Lakhs, with a fresh issue component of Rs. 10,454.40 Lakhs.
Utilized Rs. 7,213.10 Lakhs for long-term working capital requirements out of an allocated Rs. 7,267.50 Lakhs.
Confirmed zero deviation in the utilization of funds raised through the Initial Public Offer as of December 31, 2025.
👀 What to Watch
Investors should monitor the detailed profit and loss statements to evaluate if the deployment of IPO funds into working capital is translating into revenue growth. The clean audit report and transparent fund utilization are positive indicators of corporate governance.
Cipla Faces GST Inspection at Maharashtra Facilities; Operations Unaffected
The Maharashtra Goods & Service Tax Department initiated inspection and search proceedings at Cipla's facilities and offices on February 5, 2026. The search, conducted under Section 67 of the MGST Act, focuses on tax payments, input tax credit claims, and refunds. While the proceedings are ongoing, the company has stated there is currently no financial impact or disruption to operations. Investors should monitor for any subsequent tax demands or penalties that might arise from this investigation.
Key Highlights
GST Department, Maharashtra initiated search proceedings on February 5, 2026, at 12:30 PM.
Investigation covers tax payments, input tax credit (ITC) claims, and refund processes.
Action taken under Section 67(1) and 67(2) of the Maharashtra GST Act, 2017.
Company reports no immediate financial impact or operational disruption due to the search.
👀 What to Watch
Monitor for further disclosures regarding any tax demand notices or penalties resulting from this inspection. No immediate sell-off is warranted as operations remain normal.
WIPL Announces Financial Results for Quarter Ended December 31, 2025
The Western India Plywoods Limited (WIPL) has officially submitted its financial results for the quarter and nine-month period ended December 31, 2025. The board met on February 5, 2026, to approve the financial statements, ensuring compliance with regulatory disclosure norms. While specific revenue and profit figures were not detailed in the summary brief, the filing marks a critical periodic update for shareholders. Investors should now look for the detailed line-item performance to assess the company's margin stability in the wood products sector.
Key Highlights
Board meeting concluded on February 5, 2026, to approve Q3 results.
Financial results submitted for the period ending December 31, 2025.
The announcement confirms adherence to SEBI listing obligations and disclosure requirements.
Results cover both the standalone quarter and the cumulative nine-month period of the fiscal year.
👀 What to Watch
Investors should examine the full financial disclosure for specific trends in raw material costs and net profit margins compared to the previous year. Monitor the stock for any price volatility following the earnings release.
Cipla Q3 FY26: Revenue flat at Rs 7,074 Cr; EBITDA margin dips to 17.7% on Revlimid decline
Cipla reported flat year-on-year revenue of Rs 7,074 crores for Q3 FY26, primarily impacted by a sharp decline in generic Revlimid sales. The One-India business remained a bright spot with 10% growth, while the North America segment recorded $167 million in revenue. Profitability was pressured, with EBITDA margins falling to 17.7% and PAT at Rs 676 crores, which included a Rs 276 crore exceptional item for labor code changes. Management lowered the full-year FY26 EBITDA margin guidance to approximately 21% due to Lanreotide supply disruptions and increased R&D investments.
Key Highlights
Revenue stood at Rs 7,074 crores (flat YoY) with EBITDA margin at 17.7% excluding other income.
One-India business grew 10% YoY, with the respiratory segment crossing Rs 5,000 crores in IPM.
Lanreotide supply is temporarily paused due to partner FDA issues, with resupply expected only in H1 FY27.
R&D spending increased by 37.4% YoY to Rs 494 crores (7% of revenue) to support the future pipeline.
Net cash position remains strong at Rs 10,229 crores despite dividend payments and acquisitions.
👀 What to Watch
Investors should be cautious due to the lowered margin guidance and Lanreotide supply issues, though the strong India growth and healthy cash balance provide long-term support. Monitor the progress of the Indore facility re-inspection and the transition to new leadership under Achin Gupta.
Cipla Announces New Leadership Team and KMP Changes Effective April 1, 2026
Cipla Limited has announced a transition in its Key Managerial Personnel (KMP) and authorized officers, effective from April 1, 2026. The Board has designated Mr. Achin Gupta as the Managing Director and Global CEO, while Mr. Ashish Adukia will serve as the Global CFO. These individuals, along with the Company Secretary and Global General Counsel, are authorized to determine the materiality of events for SEBI disclosures. The announcement follows a board meeting held on January 23, 2026, ensuring a planned leadership succession for the pharmaceutical giant.
Key Highlights
Mr. Achin Gupta appointed as Managing Director and Global CEO effective April 1, 2026
Mr. Ashish Adukia designated as the Global Chief Financial Officer
Ms. Meera Vanjari (Global General Counsel) and Mr. Rajendra Chopra (CS) included in the authorized KMP list
Changes are made under Regulation 30(5) of SEBI Listing Regulations for materiality disclosures
The board meeting approving these changes concluded at 2:00 p.m. IST on January 23, 2026
👀 What to Watch
Investors should monitor the transition for any changes in corporate strategy or capital allocation under the new leadership. No immediate action is required as the effective date is over two months away.
Cipla Q3 FY26: PAT Drops 57% YoY to ₹676 Cr; EBITDA Margins Contract to 17.7%
Cipla reported a challenging Q3 FY26 with flat revenue growth of 0.02% YoY at ₹7,074 crore. Profitability took a significant hit as EBITDA fell 36.9% to ₹1,255 crore and PAT plummeted 57% to ₹676 crore, impacted by rising material costs and exceptional items. While the India business showed resilience with 10% growth in branded prescriptions, the North America segment faces temporary headwinds due to a manufacturing pause for Lanreotide. The company maintains a very strong balance sheet with a net cash position of ₹10,229 crore.
Key Highlights
Revenue remained nearly flat at ₹7,074 crore compared to ₹7,073 crore in Q3 FY25.
EBITDA margins compressed significantly to 17.7% from 28.1% in the previous year's quarter.
One India business contributed 49% of total revenue, with Respiratory therapy outperforming the market by 400+ bps.
North America revenue stood at $167 million, with Albuterol maintaining a #1 market share of 22%.
Net cash position strengthened to ₹10,229 crore, providing significant capital for strategic M&A like the Inzpera acquisition.
👀 What to Watch
Investors should monitor the recovery of EBITDA margins and the timeline for the re-supply of Lanreotide in the US market. While the India growth story and Pfizer partnership are positive, the sharp decline in quarterly profitability warrants a cautious outlook in the near term.
Cipla Q3 FY26: PAT Drops 57% YoY to ₹676 Cr Amid US Revenue Decline
Cipla reported flat revenue of ₹7,074 crore for Q3 FY26, as a 10% growth in the India business was offset by a 22% decline in North American sales following lower gRevlimid contributions. Profitability was significantly impacted, with EBITDA falling 36.9% to ₹1,255 crore and PAT declining 57% to ₹676 crore. The company increased its R&D spend by 37.4% to ₹494 crore to support its future pipeline, including four major respiratory launches planned for FY27. Despite the earnings pressure, Cipla maintains a robust net cash position of ₹10,229 crore.
Key Highlights
Consolidated PAT fell 57% YoY to ₹676 crore, while EBITDA margins contracted sharply to 17.7% from 28.1%.
India business grew 10% YoY to ₹3,457 crore, with the chronic therapy mix improving to 62.3%.
North America revenue declined 22% YoY to $167 million due to the anticipated drop in gRevlimid sales.
R&D investment rose 37.4% YoY to ₹494 crore, representing 7% of total sales to drive future filings.
Maintained a strong balance sheet with a net cash position of ₹10,229 crore as of December 2025.
👀 What to Watch
Investors should brace for short-term volatility following the significant margin contraction and profit miss. The long-term outlook depends on the successful launch of the FY27 respiratory pipeline, including gAdvair, to replace lost gRevlimid revenue.
Cipla's Top-3 US Product Lanreotide Supply Paused Until H1 FY27 Following USFDA Observations
Cipla has confirmed a temporary production halt for Lanreotide Injection, a top-three product for its US subsidiary, following a USFDA inspection of its exclusive supplier, Pharmathen. The inspection at the Greece facility resulted in 9 observations, leading to a pause in manufacturing for remediation efforts. Re-supply to the US market is only expected to resume in the first half of FY 2026-27. This disruption is likely to impact Cipla's US revenue stream significantly until normal operations resume.
Key Highlights
Lanreotide Injection is a top 3 product for Cipla USA, making it a critical revenue driver.
Exclusive supplier Pharmathen received 9 USFDA Form 483 observations at its Greece plant.
Supply is expected to remain limited until H1 FY 2026-27, indicating a disruption of over 12 months.
The company is monitoring supply levels and is committed to remediation to restore stable supply.
👀 What to Watch
Investors should expect near-term pressure on US sales and margins; monitor management commentary for specific revenue loss estimates and remediation progress.
Uniply Industries Schedules 18th SCC Meeting to Discuss Liquidation Extension
Uniply Industries Limited, currently undergoing liquidation, has convened its 18th Stakeholders Consultation Committee (SCC) meeting for December 12, 2025. The primary agenda is to discuss the extension of the liquidation period, which is currently slated to end on March 31, 2025. The meeting will also address the resignation of Mr. Anil Patel, a director of Uniply Decor Limited. This indicates that the winding-up process is facing delays and requires more time for asset realization or settlement.
Key Highlights
18th Stakeholders Consultation Committee (SCC) meeting scheduled for December 12, 2025.
Proposal to extend the liquidation period beyond the current deadline of March 31, 2025.
Discussion on the resignation of Mr. Anil Patel from the board of Uniply Decor Limited.
The company is operating under the supervision of Liquidator Santhanam Rajashree.
👀 What to Watch
Investors should exercise extreme caution as liquidation typically results in zero or negligible recovery for equity shareholders. Avoid taking any new positions in the stock as the company is being legally wound up.
Uniply Industries to Discuss Liquidation Extension Beyond March 2025 in 18th SCC Meeting
Uniply Industries Limited, currently in liquidation, has scheduled its 18th Stakeholders Consultation Committee (SCC) meeting for December 12, 2025. The primary agenda involves seeking an extension for the liquidation period, which is presently slated to conclude on March 31, 2025. Additionally, the committee will discuss the resignation of Mr. Anil Patel from the board of Uniply Décor Limited. This process is being conducted under the Insolvency and Bankruptcy Board of India (Liquidation Process) Regulations, 2016.
Key Highlights
18th Stakeholders Consultation Committee meeting scheduled for December 12, 2025
Proposal to extend the liquidation period beyond the current deadline of March 31, 2025
Discussion on the resignation of Mr. Anil Patel, director of Uniply Décor Limited
Proceedings managed by Liquidator Santhanam Rajashree under IBBI regulations
👀 What to Watch
As the company is in the liquidation phase, equity shareholders typically face a total loss of capital. Investors should avoid any fresh positions and monitor the liquidation updates for final settlement details.
India Pesticides Appoints Former CBDT Chairman Arun Kumar Jain as Independent Director
India Pesticides Limited (IPL) has appointed Mr. Arun Kumar Jain as an Additional Non-Executive Independent Director for a five-year term, pending shareholder approval. Mr. Jain is a distinguished former Chairman of the Central Board of Direct Taxes (CBDT) with extensive expertise in tax laws, financial analysis, and public administration. The board has also approved the reconstitution of its committees and initiated a postal ballot process for this appointment. Shareholders can participate in the e-voting process from February 5 to March 6, 2026, with the cut-off date set for January 28, 2026.
Key Highlights
Appointment of Mr. Arun Kumar Jain as Additional Non-Executive Independent Director for a 5-year tenure.
Mr. Jain is a former IRS officer (1978 batch) and retired Chairman of the Central Board of Direct Taxes (CBDT).
Postal ballot e-voting period scheduled from February 5, 2026, to March 6, 2026.
The Board approved the reconstitution of various committees following the new appointment.
Cut-off date for shareholder eligibility for the postal ballot is January 28, 2026.
👀 What to Watch
The appointment of a high-profile former tax authority head is a positive signal for corporate governance and regulatory compliance. Investors should view this as a strengthening of the board's oversight capabilities.
Cipla Clarifies on 9 USFDA Observations at Partner Pharmathen's Greece Facility
Cipla has confirmed that its supply partner, Pharmathen International S.A., received nine inspectional observations (Form 483) from the USFDA. The inspection occurred at Pharmathen's Rodopi, Greece facility between November 10 and November 21, 2025. This facility manufactures Lanreotide Injection for Cipla's US subsidiary, a key product in its portfolio. The company is currently evaluating the material impact of these observations on its US operations.
Key Highlights
USFDA issued 9 inspectional observations in Form 483 to supply partner Pharmathen International S.A.
The affected facility in Rodopi, Greece, manufactures Lanreotide Injection for Cipla USA Inc.
Inspection was conducted over an 11-day period from November 10 to November 21, 2025.
Cipla's stock price fell 4% following media reports of these observations prior to the official clarification.
👀 What to Watch
Investors should monitor the severity of the 9 observations as they could lead to supply disruptions for Lanreotide in the US market. Maintain a cautious stance until the company provides a detailed impact assessment or remediation timeline.
India Pesticides Secures Regulatory Approval for Fungicide Formulation in Australia
India Pesticides Limited (IPL) has successfully obtained regulatory registration for its fungicide formulation in Australia as of December 26, 2025. This approval marks a significant milestone in the company's strategy to expand its international footprint and diversify its geographical revenue streams. The entry into the Australian market is expected to contribute to enhanced export revenues in the coming quarters. This development highlights the company's focus on high-margin international markets and its capability to meet stringent global regulatory standards.
Key Highlights
Obtained regulatory registration for fungicide formulations in Australia on December 26, 2025
Strategic expansion into the international market aimed at boosting export revenue growth
Strengthens the company's global presence in the pesticides and agrochemicals sector
The approval allows the company to cater specifically to the Australian agricultural market
👀 What to Watch
Investors should view this as a positive growth catalyst that diversifies revenue risk away from the domestic market. Monitor management commentary in upcoming earnings calls for specific revenue guidance from the Australian region.
Cipla Signs 5-Year Exclusive Marketing Agreement with Pfizer for Four Key Brands
Cipla has entered into a strategic 5-year exclusive agreement with Pfizer India to market and distribute four prominent brands: Corex, Dolonex, Neksium, and Dalacin C. Under this partnership, Cipla will utilize its vast distribution network to scale these brands, while Pfizer continues to handle manufacturing and supply. The deal involves no upfront payment, representing a low-risk, high-potential expansion of Cipla's domestic portfolio. This collaboration is expected to strengthen Cipla's market share in the cough syrup, pain management, and antibiotic segments.
Key Highlights
Exclusive 5-year rights to market and distribute Corex Dx/LS, Dolonex, Neksium, and Dalacin C in India.
Partnership leverages Cipla's status as India's 3rd largest pharma company with extensive distribution reach.
Zero upfront consideration paid, with commercial terms based on ongoing supply and marketing arrangements.
Pfizer will continue to manufacture and source the medicines, ensuring consistent product quality.
👀 What to Watch
This is a value-accretive deal that enhances Cipla's domestic portfolio with established brands; investors should maintain a positive outlook as this boosts revenue potential without capital expenditure.
Cipla launches Yurpeak® (Tirzepatide) in India for Obesity and Type 2 Diabetes
Cipla has launched Yurpeak® (Tirzepatide) in India for treating obesity and type 2 diabetes, under an agreement with Eli Lilly. Yurpeak® is a one-weekly injectable therapy and will be available in six strengths, ranging from 2.5 mg to 15 mg. Cipla will leverage its distribution network to make Yurpeak® available across India, including regions beyond metro cities. The price will be the same as Mounjaro®. This launch expands Cipla's presence in chronic disease management.
Key Highlights
Yurpeak® is available in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep’25)
Cipla will distribute Yurpeak® at the same price as Mounjaro®
👀 What to Watch
Investors should monitor the market response to Yurpeak® and its impact on Cipla's revenue and profitability in the chronic disease segment. Keep an eye on Cipla's distribution strategy and market penetration in both metro and non-metro areas.
India Pesticides Obtains Herbicide Formulation Registration in Serbia
India Pesticides Limited (IPL) has successfully obtained regulatory approval for its herbicide formulation in Serbia, as announced on December 6, 2025. This registration marks a significant milestone in the company's strategy to expand its international footprint and diversify its geographic revenue streams. The approval is expected to contribute to enhanced export revenues and strengthen IPL's presence in the European agrochemical market. This move aligns with the company's focus on high-margin international pesticide sales.
Key Highlights
Received regulatory approval for herbicide formulation registration in Serbia on December 6, 2025.
The product is categorized under Pesticides and is specifically targeted for the international market.
Management expects this approval to contribute significantly to the company's export revenue growth.
The registration strengthens the company's global presence and market penetration in the Balkan region.
👀 What to Watch
Investors should track the growth in export revenue share in upcoming quarterly reports to assess the financial impact of this and other international registrations.
JKIPL welcomes RBI's growth policy, rupee at ₹90/USD boosts exports
Jinkushal Industries Limited (JKIPL) welcomes the RBI's decision to reduce the policy repo rate by 25 basis points to 5.25%. The company highlights the rupee's movement from ₹83 per US dollar in December 2024 to ₹90 per US dollar in December 2025, which significantly improves export competitiveness. JKIPL notes that a USD 100,000 export invoice now yields nearly ₹90 lakh compared to ₹83 lakh in December 2024, resulting in a gain of roughly ₹7 lakh per invoice. This strengthens margins and enables reinvestment in technology and global reach.
Key Highlights
RBI reduced the policy repo rate by 25 basis points to 5.25%.
Rupee moved from approximately ₹83 per US dollar to around ₹90 per US dollar.
USD 100,000 export invoice yielded about ₹83 lakh in December 2024.
USD 100,000 export invoice realizes nearly ₹90 lakh in December 2025.
Gain of roughly ₹7 lakh per invoice due to currency movement.
👀 What to Watch
Investors should monitor JKIPL's export performance and margin improvements due to the favorable exchange rate. Keep an eye on how the company reinvests the increased revenue from exports.
Cipla completes 100% acquisition of Inzpera Healthsciences
Cipla Limited has announced the completion of its acquisition of Inzpera Healthsciences Limited. The company acquired a 100% stake in Inzpera on December 4, 2025. As a result of this acquisition, Inzpera Healthsciences Limited has become a wholly-owned subsidiary of Cipla. This acquisition will likely expand Cipla's portfolio in the health and wellness segment.
Key Highlights
Cipla acquired 100% stake in Inzpera Healthsciences Limited
Acquisition completed on December 4, 2025
Inzpera is now a wholly-owned subsidiary of Cipla
👀 What to Watch
Investors should monitor Cipla's future performance and integration of Inzpera to assess the long-term benefits of this acquisition. Keep an eye on how this acquisition impacts Cipla's market share and profitability in the health and wellness sector.
